Osthole ameliorates acute myocardial infarction in rats by decreasing the expression of inflammatory-related cytokines, diminishing MMP-2 expression and activating p-ERK

JUAN DUAN¹, YU YANG¹, HONG LIU¹, PENG-CHENG DOU² and SHENG-YU TAN¹

Departments of ¹Geriatrics and ²Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China

Received May 15, 2015; Accepted October 23, 2015

DOI: 10.3892/ijmm.2015.2402

Abstract. Osthole, the active constituent of Cnidium monnieri extracts, has been shown to have a diverse range of pharmacological properties. In the present study, we aimed to evaluate the cardioprotective effects of osthole in a rat model of acute myocardial infarction (AMI). The rats with AMI were treated with 1, 3 and 10 mg/kg of osthole or the vehicle for 4 weeks. The infarct size of the rats with AMI was measured and was significantly decreased by treatment with osthole. The levels of Toll-like receptors 2/4 (TLR2/4) and nucleotide-binding oligomerization domain-containing protein 1/2 (NOD1/2) were also detected using commercially available kits. The nuclear factor-κB (NF-κB), tumor necrosis factor-α (TNF-α), interleukin (IL)-1β and IL-6 levels in whole blood from rats with AMI were also detected using commercially available kits. The levels of Toll-like receptors 2/4 (TLR2/4) and nucleotide-binding oligomerization domain-containing protein 1/2 (NOD1/2) were also detected by RT-qPCR. Moreover, the protein expression levels of endothelial nitric oxide synthase (eNOS) and mitogen-activated protein kinase (MAPK) cascades, including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38, cyclooxygenase-2 (COX-2), as well as matrix metalloproteinase-2 (MMP-2) were all assayed by western blot analysis. Our results revealed that osthole markedly decreased the infarct size, and the levels of CK, CK-MB, LDH and cTnT in the rats with AMI, and that these cardioprotective effects may be associated with the inhibition of inflammatory reactions, the reduction in MMP-2 activity and the activation of MAPK cascades.

Introduction

Acute myocardial infarction (AMI) results in myocardial necrosis and is caused by acute coronary artery disease and persistent ischemia and hypoxia. There have been many documented clinical cases of severe and persistent pain behind the sternum, which cannot be completely relieved by rest and nitrate esters. AMI is associated with an increase in serum myocardial enzyme activity and progressive changes in the electrocardiogram, and can cause arrhythmia, heart failure or shock and is often fatal (1). This disease is common in Europe and America, and approximately 620,000 Americans suffer from heart disease in the US each year (2).

During the development of AMI, the inflammatory reaction plays a key role in all types of damage factors, and it can be viewed as the intermediary link between the generation and development of various injury factors and damage to cardiac muscle. Under normal circumstances, inflammatory cells and vascular endothelial cells do not attach, or hardly attach; however, following stimulation with inflammatory factors, adhesion molecules are rapidly activated and help inflammatory cells to attach and accumulate in endothelial cells; this is followed by the release of inflammatory mediators and damage to endothelial cells (3).

Matrix metalloproteinases (MMPs) are a family of enzymes that contain at least 26 members. Previous research has indicated that MMPs can adjust and control the synthesis and degradation of the extracellular matrix (ECM), and they are the main factor contributing to plaque rupture and can thus participate in ventricular reconstruction (4). MMP-2 and MMP-9 are the most important members of MMPs, and both are secreted by vascular smooth muscle cells. The expression of these two MMPs is significantly increased in patients with atherosclerotic plaque, which can cause specific degradation of the ECM and may also cause plaque rupture, thus leading to the development of AMI (5).

Mitogen-activated protein kinases (MAPKs) are signaling mediators that connect cell-surface receptors to intracellular critical regulatory targets. There is emerging evidence indicating that the MAPK cascades regulate a variety of cellular activities, such as cell growth, survival and death (6). The MAPK family includes at least three distinct subgroups, namely extracellular...

Correspondence to: Dr Sheng-Yu Tan, Department of Geriatrics, The Second Xiangya Hospital of Central South University, 139 Renmin Road, Changsha, Hunan 410011, P.R. China

E-mail: sytdr2015@163.com

Key words: osthole, acute myocardial infarction, inflammatory, endothelial nitric oxide synthase, mitogen-activated protein kinases, matrix metalloproteinase-2
signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK), and p38 in mammalian cells (7). A previous study demonstrated the transient activation of ERK in cultured rat neonatal cardiac myocytes following exposure to hydrogen peroxide; the inhibition of the activation of ERK exacerbated cardiomyocyte apoptosis (8). Moreover, it has been demonstrated that the JNK pathway is specifically activated following the transfection of cultured neonatal rat cardiac myocytes with recombinant adenoviral vectors expressing a constitutively active mutant of MKK7 (or JNKK2), an upstream activator of JNK, which contributed to the induction of hypertrophic responses (9). As regards the role of the p38 signaling pathway in cardiomyocyte apoptosis, a previous study demonstrated that p38 was activated in neonatal rat cardiomyocytes due to ischemia and that the inhibition of p38 protected cardiac myocytes from apoptosis (10).

It has also been previously reported that osthole, the active constituent of Cnidium monnieri extracts, has anti-inflammatory and hepatic fat-oxidizing properties (11). Osthole has been shown to effectively inhibit the activation of the MMP-2 promoter and its enzyme, which may be one of the mechanisms involved in cellular migration and invasion (12). The present study is the first, to the best of our knowledge, which investigated the hypothesis that osthole decreases the expression of Toll-like receptor (TLR)2 and TLR4, nucleotide-binding oligomerization domain-containing protein (NOD)1, NOD2, increases endothelial nitric oxide synthase (eNOS) and decreases cyclooxygenase-2 (COX-2) expression in a rat model of AMI. We wished to examine whether these effects are mediated through the inhibition of inflammatory reactions, a decrease in MMP-2 expression and the activation of MAPK cascades.

Materials and methods

Drugs, reagents and kits. The chemical structure of osthole is depicted in Fig. 1. Osthole (with a purity of 95%; Sigma-Aldrich Co., St. Louis, MO, USA) was dissolved in physiological saline. Casein kinase (CK), the MB isoenzyme of creatine kinase (CK-MB), lactate dehydrogenase (LDH) and cardiac troponin T (cTnT) commercial kits were purchased from Sangon Biotech (Shanghai, China). Nuclear factor-κB (NF-κB), tumor necrosis factor-α (TNF-α), interleukin (IL)-1β and IL-6 commercial kits were purchased from Jiancheng Bioengineering (Nanjing, China). A BCA protein assay kit was purchased from Tiangen (Beijing, China). Caspase-3 and caspase-9 activity assay kits were purchased from Sangon Biotech.

Experimental animals. A total of 50 healthy male Wistar rats (weighing 220-250 g) were obtained from the Experimental Animal Center of the Second Xiangya Hospital of Central South University (Changsha, China). All experimental procedures were approved by the Second Xiangya Hospital of Central South University and were performed in accordance with the ethical standards of our institution. All experimental rats were allowed to acclimatize in enriched plastic cages and had free access to food and clean drinking water.

Induction of AMI and group design. The rats were operated on after being intraperitoneally anesthetized using sodium pentobarbitone (40 mg/kg). The model of AMI was created by ligating the left anterior descending coronary artery, as previously described (13). The successful establishment of the rat model of AMI was confirmed by the presence of regional cyanosis on the myocardial surface and represented by the elevation of the ST-segment. All experimental rats were randomly divided into 5 groups as follows (n=10 in each group): i) the sham-operated group; ii) the vehicle-treated group; iii) the group treated with 1 mg/kg osthole; iv) the group treated with 3 mg/kg osthole and v) the group treated with 10 mg/kg osthole. The rats in the osthole-treated groups were treated with various doses of osthole (1, 3 and 10 mg/kg) once a day for 4 weeks. The dosage and dosage frequency were determined on the basis of the findings of a previous study (14). Rats in the sham-operated group were not operated upon. Rats in the vehicle-treated group underwent the procedure of AMI after being injected with the same volume of physiological saline. Rats in the osthole-treated group underwent the procedure of AMI after being injected with osthole though the tail vein. The rats were treated with physiological saline or osthole once a day for 4 weeks. The rats were operated on (occlusion of the coronary artery) 30 min after the final injection. The coronary artery was occluded with a 1-2 mm of 5-0 silk suture for encircling the left anterior descending coronary artery below the left atrial appendage.

Measurement of infarct size. The hearts of the experimental rats were immediately measured through the aorta and washed with physiological saline. The coronary artery was occluded and after 6 h, the left ventricle was placed in a freezer at -80°C for 5-10 min. Subsequently, it was sliced into 2-mm-thick sections in order to measure the infarct size. The infarct size of the rats was measured using 1% 2,3,5-triphenyltetrazolium chloride (1.5%; Sigma-Aldrich Co.) at 37°C for 30 min in the dark (15,16). The area of the heart without color was regarded as the ischemic heart muscle, and the area which was colored brick red was regarded as the normal myocardium. The size of the infarct area was measured by calculating the volume and weight as a percentage of the left ventricle.

Measurement of levels of plasma cardiac marker enzymes. Serum samples of rats were extracted from the vena cava following the occlusion of the coronary artery for 6 h. Serum samples were then centrifuged at 1,000 x g for 25 min and were saved for measurement at -20°C. The CK, CK-MB, LDH and cTnT activities in the rats were analyzed using a series of commercial kits (Sangon Biotech) according to the manufacturer's instructions.

RNA extraction and reverse transcription-quantitative PCR (RT-qPCR). The heart samples were collected, and total RNA was extracted and purified using TRIzol reagent following the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). Subsequently, 1 µg of total RNA from the heart samples was used to perform first-strand cDNA synthesis and this first-strand cDNA was transcribed into cDNA using random hexamers (Promega, Beijing, China) according to the manufacturer's instructions. The StepOnePlus real-time PCR system was used to perform quantitative (real-time) PCR (qPCR) using power SYBR-Green PCR Master Mix (Applied Biosystems, Foster, CA, USA). Ten microliters of power SYBR-Green PCR master mix, 1 µl of cDNA, 2 µl of primers and 7 µl of PCR-grade water were blended and PCR was then performed. The reactions were...
performed at 95°C for 10 min, followed by 35 cycles of 95°C for 30 sec, 58°C for 45 sec, and 72°C 30 sec, 4°C for saving. The sequences for the gene-specific primers are listed in Table I.

Western blot analysis. The heart samples were lysed in ice-cold RIPA buffer (Beyotime Biotechnology, Natong, China) containing 10 mM Tris (pH 8.0), 150 mM NaCl, 1% glycerol, 1% NP-40, 5 mM EDTA and protease inhibitor cocktail. An equal amount of protein (60 μg) was separated by electrophoresis on 8 or 10% sodium dodecyl sulfate (SDS)-polyacrylamide (SDS-PAGE) gels and transferred onto nitrocellulose membranes (Millipore, Billerica, MA, USA). After blocking in 5% fat-free milk, the membranes were incubated with the following primary antibodies: rabbit anti-eNOS (1:300; sc-49055), rabbit anti-COX-2 (1:500; sc -7951), mouse anti-phosphorylated (p-)JNK (Thr183/Tyr185) (1:200; sc-293136), rabbit anti-p-ERK (Tyr204) (1:200; sc-377400) (all from Santa Cruz, CA, USA) and mouse anti-β-actin (1:2,000; KC-5A08; Kangchen, Beijing, China), overnight at 4°C. The membranes were then treated with horseradish peroxidase-conjugated goat anti-rabbit antibody (1:5,000; sc-2004) or goat anti-mouse antibody (1:5,000; sc-2005) (both from Santa Cruz Biotechnology, Inc.) and peroxidase-conjugated goat anti-rabbit antibody (1:5,000; sc-101758), mouse anti-p-p38 MAPK (Tyr182) (1:200; sc -101758), mouse anti-p-ERK (Tyr204) (1:200; sc-377400) (all from Santa Cruz Biotechnology, Inc.). The heart samples were lysed in 5% fat-free milk in 5% SDS-PAGE (SDS)-polyacrylamide (SDS-PAGE) gels and transferred onto nitrocellulose membranes (Millipore, Billerica, MA, USA). After blocking in 5% fat-free milk, the membranes were incubated with the following primary antibodies: rabbit anti-eNOS (1:300; sc-49055), rabbit anti-COX-2 (1:500; sc -7951), mouse anti-phosphorylated (p-)JNK (Thr183/Tyr185) (1:200; sc-293136), rabbit anti-p-ERK (Tyr204) (1:200; sc-377400) (all from Santa Cruz Biotechnology, Inc.), Santa Cruz, CA, USA) and mouse anti-β-actin (1:2,000; KC-5A08; Kangchen, Beijing, China), overnight at 4°C. The membranes were then treated with horseradish peroxidase-conjugated goat anti-rabbit antibody (1:5,000; sc-2004) or goat anti-mouse antibody (1:5,000; sc-2005) (both from Santa Cruz Biotechnology, Inc.) and peroxidase-conjugated goat anti-rabbit antibody (1:5,000; sc-101758), mouse anti-p-p38 MAPK (Tyr182) (1:200; sc -101758), mouse anti-p-ERK (Tyr204) (1:200; sc-377400) (all from Santa Cruz Biotechnology, Inc.).

Determination of plasma nitrite production. Nitric oxide (NO) production was determined by measuring the plasma supernatant for nitrite using Griess reagent (Promega). The absorbance was recorded at a wavelength of 540 nm, and the nitrite concentration was determined using sodium nitrite as the standard.

Measurement of NF-κB, tumor necrosis factor-α (TNF-α), IL-1β and IL-6 levels. Whole blood of rats was collected into a serum separator tube for 30 min after a 6-h ischemic period. Serum samples were then centrifuged at 1,000 x g for 25 min and were kept for the measurement at -20°C. A commercial ELISA kit was used to measure the serum levels of NF-κB, TNF-α, IL-1β and IL-6 in rats according to the manufacturer’s instructions.

Measurement of MMP-2 levels. Following treatment with osthole, MMP-9 markers were detected by gelatin zymography assays. A total of 50 μl of samples was absorbed into a new centrifuge tube, and an equal volume of sample buffer was then added to the centrifuge tube. The miscible liquids were subjected to 10% SDS-PAGE electrophoresis on a gel impregnated with 0.1% gelatin. The gel was washed 3 times for 20 min at room temperature in 2.5% Triton X-100 to remove the SDS after electrophoresis. The gel was incubated in reaction buffer at 37°C for 12 h. Subsequently, the gel was stained with 0.05% Coomassie brilliant blue R-250.

Caspase-3 and caspase-9 activity assay. Approximately 50 μg cardiac cytosolic protein was incubated in solution buffer at 37°C for 30 min. Briefly, caspase-3 and caspase-9 activity was measured using a caspase-3 and caspase-9 activity assay kit (Sangon Biotech). A total of 10 μl protein cell lysate per sample was added to 80 μl reaction buffer with 10 μl substrate Asp-Glu-Val-Asp (DEVD)-p-nitroaniline (pNA) and incubated at 37°C for 4-6 h. Caspase-3 activation was measured using a microplate reader (Bio-Rad, Hercules, CA, USA) at an absorbance of 405 nm. The change in fluorescence (excitation at 400 nm) was detected at a wavelength of 405 nm.

Statistical analysis. Data are expressed as the means ± SD and were analyzed using SPSS 17.0 software. Differences between the experimental groups were analyzed using the Student’s t-test. Values of p<0.05 were considered to indicate statistically significant differences.

Results

Effects of osthole on myocardial infarct size. The chemical structure of osthole is illustrated in Fig. 1. Firstly, we examined the effects of osthole on the myocardial infarct size in the rats with AMI. After the operation, the rats with AMI were treated with various doses (1, 3 and 10 mg/kg) of osthole for 4 weeks.

Table I. Sequences of gene-specific primers used for RT-qPCR.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer sequence (5’-3’)</th>
<th>Product size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLR2</td>
<td>TCTCCCATTTCCGGTCTTTT</td>
<td>125</td>
</tr>
<tr>
<td>TLR4</td>
<td>GAAGCTGGTGGCTTGTTGGA</td>
<td>213</td>
</tr>
<tr>
<td>NOD1</td>
<td>GTCACTGAGGTCCATCTGAAC</td>
<td>363</td>
</tr>
<tr>
<td>NOD2</td>
<td>CATGTTGCTAGGTGTCTCT</td>
<td>226</td>
</tr>
<tr>
<td>COX-2</td>
<td>CAAATCTCTCTGTTCCCACCCAT</td>
<td>173</td>
</tr>
<tr>
<td>β-actin</td>
<td>AGCGAGCAGTCCCCCAAAGTT</td>
<td>284</td>
</tr>
</tbody>
</table>

TLR, Toll-like receptor; NOD, nucleotide-binding oligomerization domain-containing protein; COX-2, cyclooxygenase-2.
As shown in Fig. 2, treatment with 1, 3 and 10 mg/kg of osthole significantly inhibited the myocardial infarct size of the rats with AMI (p<0.01), compared with the vehicle-treated group (Fig. 2).

**Effects of osthole on the levels of plasma cardiac marker enzymes.** We examined the effects of osthole on the levels of plasma cardiac marker enzymes. CK, CK-MB, LDH and cTnT activities were measured to analyze its curative effects on AMI. CK, CK-MB, LDH and cTnT activities were higher in the vehicle-treated group compared to the sham-operated group (Table II). However, treatment with osthole significantly inhibited the CK, CK-MB, LDH and cTnT activities in the rats with AMI in a dose-dependent manner (p<0.05 and p<0.01) compared to the vehicle-treated group (Table II).

**Effects of osthole on TLR2 and TLR4 gene expression.** Our results revealed that treatment with osthole markedly decreased the mRNA expression levels of TLR2 and TLR4 in the rats with AMI compared to the vehicle-treated group (Fig. 3).

**Effects of osthole on NOD1 and NOD2 gene expression.** After 4 weeks of osthole treatment, RT-qPCR was performed to measure the mRNA expression levels of NOD1 and NOD2 in the rats with AMI. It should be noted that there was no significant difference in the mRNA expression of NOD1 between the sham-operated group and the vehicle-treated group (Fig. 4A). Following treatment of the rats with AMI with osthole at the doses of 1, 3 and 10 mg/kg, NOD1 mRNA expression was significantly decreased in a dose-dependent manner (p<0.01), compared to the vehicle-treated group (Fig. 4A). As regards NOD2 mRNA expression, a significant increase was observed in the vehicle-treated group (p<0.01), in comparison with the sham-operated group, although NOD2 expression was significantly (p<0.01) downregulated in a dose-dependent manner following treatment with osthole (Fig. 4B). Thus, the administration of osthole at the doses of 1, 3 and 10 mg/kg reversed the increase in NOD2 mRNA expression in the rats with AMI (Fig. 4B).

**Effects of osthole on eNOS expression.** We examined the effects of osthole on eNOS expression in the rats with AMI; eNOS protein expression and production were examined in the rats in the different groups. As depicted in Fig. 5A and B, following the induction of AMI, eNOS protein expression markedly decreased in the vehicle-treated group (p<0.01) in comparison with the sham-operated group. Notably, compared to the vehicle-treated group, treatment with osthole at 1, 3 and 10 mg/kg significantly increased eNOS protein expression in the rats with AMI (p<0.01; Fig. 5A and B). We also noted that nitrite production was higher in the sham-operated group (Fig. 5C). Moreover, following treatment with osthole (1, 3 and 10 mg/kg), a marked increase in nitrite production was noted (p<0.01) compared to the vehicle-treated group.

**Effects of osthole on COX-2 expression.** To examine the effects of osthole on COX-2 expression in the rats with AMI, we measured the expression levels of COX-2 at the mRNA and protein level in the different groups. The results revealed that the rats with AMI exhibited an increase in COX-2 expression at both the mRNA (gene) and protein level in comparison to the sham-operated group (Fig. 6). However, treatment with osthole (1, 3 and 10 mg/kg) significantly inhibited the upregulation of COX-2 expression in the rats with AMI (p<0.01), compared to the vehicle-treated group.

**Effects of osthole on the activities of NF-κB, TNF-α, IL-1β and IL-6.** We quantified the activities of NF-κB, TNF-α, IL-1β and IL-6 in the different groups of rats. As illustrated in Fig. 7, NF-κB, TNF-α, IL-1β and IL-6 activities in the rats with AMI were significantly increased (p<0.01), in comparison with the sham-operated rats. However, the levels of these inflammatory factors were significantly reduced following treatment with osthole (1, 3 and 10 mg/kg; p<0.01; Fig. 7).

**Effects of osthole on MMP-2 protein expression.** In the present study, we examined the effects of osthole on the inflamma-

---

### Table II. Effects of osthole on plasma cardiac marker enzymes.

<table>
<thead>
<tr>
<th>Groups</th>
<th>CK (U/ml)</th>
<th>CK-MB (IU/l)</th>
<th>LDH (U/l)</th>
<th>cTnT (U/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>0.24±0.03</td>
<td>79.27±6.72</td>
<td>1836.63±292.12</td>
<td>0.07±0.04</td>
</tr>
<tr>
<td>Vehicle</td>
<td>0.58±0.05a</td>
<td>189.00±9.31a</td>
<td>3713.25±367.83a</td>
<td>0.32±0.06c</td>
</tr>
<tr>
<td>1 mg/kg</td>
<td>0.41±0.04b</td>
<td>111.75±7.45c</td>
<td>3055.25±330.39b</td>
<td>0.15±0.04c</td>
</tr>
<tr>
<td>3 mg/kg</td>
<td>0.31±0.04c</td>
<td>94.47±10.99c</td>
<td>2541.25±365.82c</td>
<td>0.13±0.07c</td>
</tr>
<tr>
<td>10 mg/kg</td>
<td>0.24±0.03c</td>
<td>83.60±8.32c</td>
<td>2256.13±301.77c</td>
<td>0.12±0.03c</td>
</tr>
</tbody>
</table>

*p<0.01 vs. sham-operated (sham) group; *p<0.05 and *p<0.01 vs. vehicle-treated (vehicle) group. Rats were treated with various doses of osthole (1, 3 and 10 mg/kg). CK, casein kinase; CK-MB, MB isoenzyme of creatine kinase; LDH, lactate dehydrogenase; cTnT, cardiac troponin T.
Figure 3. Effects of osthole on Toll-like receptor (TLR) gene expression. (A) TLR2 and TLR4 (B). **p<0.01 vs. sham-operated (sham) group; ***p<0.01 vs. vehicle-treated (vehicle) group. Rats were treated with 1, 3 and 10 mg/kg of osthole.

Figure 4. Effects of (A) osthole on binding oligomerization domain (NOD)1 and (B) NOD2 gene expression. **p<0.01 vs. sham-operated (sham) group; ***p<0.01 vs. vehicle-treated (vehicle) group. Rats were treated with 1, 3 and 10 mg/kg of osthole.

Figure 5. Effects of osthole on endothelial nitric oxide synthase (eNOS) protein expression levels (A) using western blot analysis, (B) statistical analysis of eNOS protein expression levels, and (C) plasma nitrite production. **p<0.01 vs. sham-operated (sham) group; ***p<0.01 vs. vehicle-treated (vehicle) group. Rats were treated with 1, 3 and 10 mg/kg of osthole.

Figure 6. Effects of osthole on the (A) gene and (B and C) protein expression of cyclooxygenase-2 (COX-2). **p<0.01 vs. sham-operated (sham) group; ***p<0.01 vs. vehicle-treated (vehicle) group. Rats were treated with 1, 3 and 10 mg/kg of osthole.
We measured MMP-2 protein expression in the different groups of rats. Compared to the sham-operated group, the rats with AMI (vehicle-treated group) exhibited a significant increase in MMP-2 protein expression (p<0.01; Fig. 8). This AMI-induced increase in MMP-2 protein expression was reversed by treatment with osthole (p<0.01; Fig. 8).

Effects of osthole on the phosphorylation of MAPK (JNK, p38 MAPK and ERK1/2) proteins. In order to further explore the cardioprotective mechanisms of action of osthole, the phosphorylation levels of JNK, p38 MAPK and ERK1/2 (p-JNK, p-p38 and p-ERK1/2) were examined by western blot analysis. We found that compared with the sham-operated group, the rats with AMI (vehicle-treated group) exhibited an increase in p-JNK and p-p38 protein expression (p<0.01), in comparison with the sham-operated group (Fig. 9A-C); however, treatment with osthole reduced p-JNK and p-p38 expression in a dose-dependant manner. We noted that p-ERK1/2 protein expression in the vehicle-treated group was effectively suppressed, compared to the sham-operated group (Fig. 9A and D). However, treatment with osthole (1, 3 and 10 mg/kg) significantly increased p-ERK1/2 expression (p<0.01) compared to the vehicle-treated group. As expected, pre-treatment with osthole reversed the effects of AMI on MAPK signaling pathways in the rats with AMI rats.

Effects of osthole on caspase-3 and caspase-9 activities. The apoptotic pathway was also examined in the present study. We observed a significant increase in caspase-3 and caspase-9 activities in the rats with AMI (p<0.01) compared to the sham-operated group (Fig. 10). However, these effects were significantly reversed by treatment with osthole.

Discussion

In patients with AMI, the reduction of myocardial cell viability and ventricular remodeling are the main factors responsible for heart failure and even death in the long-term (17). With the widespread application of emergency thrombolysis, emergency interventional therapy and coronary bypass surgery,
the mortality rate of patients suffering from AMI has been greatly reduced and the number of survivors has increased significantly (18). In this study, we found that treatment with osthole markedly reduced the levels of CK, CK-MB, LDH and cTnT in the serum of rats with AMI. In particular, Wei et al reported that osthole was capable of reducing hyperalgesia due to lumbar disc herniation (19). In the present study, the infarct size of rats with AMI was significantly reduced following treatment with osthole; however, the exact mechanisms involved require further investigation. This reduction in the infarct size, however, indicates that osthole exerts protective effects on heart tissue and may protect against AMI (as shown in our rat model).

TLRs are an integral component of the inflammation process. TLR2 and TLR4 are the most common and most well characterized as regards inflammatory responses in AMI. They are expressed predominantly in monocytes/macrophages and neutrophils. TLR2 is involved in the recognition of inflammatory reactions in AMI and plays an important role in the immune system. The peptidoglycan subunits are recognized by the NOD family proteins, in particular by NOD1 and NOD2. NOD1 and NOD2 are involved primarily in mediating antibacterial and anti-inflammatory defenses. They are intracellular proteins involved in innate immunity and are associated with chronic inflammatory diseases in humans. In the present study, we demonstrated that there was a marked increase in TLR2, TLR4 and NOD2 gene expression in the rats with AMI compared to the sham-operated rats, and this effect was suppressed in a dose-dependent manner by treatment with osthole, implying that the cardioprotective effects of osthole are achieved through mediating TLR2/4 and NOD1/2 expression.

Previous research has demonstrated that NO exerts a cardioprotective effect against AMI. The effects of NO on myocardial infarction are associated with both its pro- and anti-apoptotic properties depending on the source of

Figure 9. Effects of osthole on phosphorylation of mitogen-activated protein kinase (MAPK) [c-Jun N-terminal kinase (JNK), p38 MAPK and extracellular signal-regulated kinase 1/2 (ERK1/2)] protein expression levels (A) using western blot analysis and (B-D) statistical analysis of (B) p-JNK, (C) p-p38 and (D) p-ERK1/2 protein expression. *p<0.01 vs. sham-operated (sham) group; **p<0.01 vs. vehicle-treated (vehicle) group. Rats were treated with 1, 3 and 10 mg/kg of osthole.

Figure 10. Effects of osthole on (A) caspase-3 and (B) caspase-9 activities. *p<0.01 vs. sham-operated (sham) group; **p<0.01 vs. vehicle-treated (vehicle) group. Rats were treated with 1, 3 and 10 mg/kg of osthole.
NO (20). NO is generated from the guanidinium group of L-arginine in an NADPH-dependent reaction catalyzed by NO synthase (NOS). At present, there are three known isozymes of NOS, including neuronal NOS (nNOS or NOS1), inducible NOS (iNOS or NOS2) and endothelial cell NOS (eNOS or NOS3). Of these isozymes, eNOS is not only expressed in the endocardium and endothelium of the coronary vasculature, but is also found in cardiac myocytes and in specialized cardiac conduction systems, such as sinoatrial and atrioventricular nodal tissues (21). It is widely accepted that NO produced from eNOS in the heart plays a critical role in coronary vasodilation and the inhibition of mitochondrial O2 consumption. A previous study indicated that myocardial injury was exacerbated in eNOS−/− mice following ischemic insults, suggesting a protective effect of eNOS-derived NO (22). In the present study, we found that osthole significantly and dose-dependently promoted the activation of eNOS and decreased COX-2 expression in rats with AMI. A previous study also demonstrated that osthole relaxed the pulmonary arteries via the Akt-eNOS-NO signaling pathway in rats (23). Yang et al also reported that osthole attenuated focal segmental glomerulosclerosis by inhibiting NF-kB-mediated COX-2 expression (24).

TNF-α, IL-1β and IL-6 are closely related to disease severity and the prognosis of patients (25). In a previous study, it has been verified that, in atherosclerosis, TNF-α, IL-1, IL-8 and other inflammatory factors are activated through NF-kB. It was verified that activated NF-kB exists in smooth muscle cells, macrophages and endothelial cells in atherosclerosis (26). Therefore, it is clear that activated NF-kB participates in the process of ventricular remodeling. In the present study, we demonstrated that osthole reduced the activities of NF-kB, TNF-α, IL-1β and IL-6 in AMI rats. A previous study found that osthole ameliorated renal ischemia-reperfusion injury by restraining the inflammatory response (27). In another previous study, osthole was also reported to weaken the inflammatory reaction following permanent middle cerebral artery occlusion in rats (28).

MMPs are secreted by myocardial cells, vascular endothelial cells, smooth muscle cells, foam cells and other cells, including the protease family that depends on Ca2+ and Zn2+. It has been demonstrated that MMPs are proteases which adjust and control the ECM, and they can promote the degradation of the ECM, accelerate the development of atheromatous plaque and lead to the formation of unstable plaque (29,30). Prior research has indicated that MMP-2 reflects the status of atherosclerotic plaque, which plays an important role in a series of processes of occurrences and the development of AMI (31). In the present study, we demonstrated that treatment with osthole decreased the expression of MMP-2. Similarly, osthole was previously found to reduce the levels of MMP-2 and MMP-9 in the A549 human lung cancer cells (32). Moreover, Yang et al reported that osthole effectively inhibited the MMP-2 promoter in breast cancer cells (33).

Emerging evidence implies that MAPK signaling cascades are involved in cardiac myocyte apoptosis. The MAPK family contains three major subgroups, namely ERK, JNK and p38 MAPK. These are activated in response to myocardial infarction. It is generally believed that the inhibition of the ERK pathway enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exacerbates myocardial injury in isolated rat hearts following ischemia-reperfusion (7). Liu et al (34) also reported that the phosphorylation of ERK was decreased in a rat model of AMI, and that treatment with baicalin potently suppressed this reduction. The present study demonstrated a marked decrease in p-ERK levels in rats with AMI, which is consistent with the results of previous studies (34) and, more importantly, there was an evident increase in the phosphorylated levels of ERK following treatment with osthole. This implies that the activation of the ERK cascade should be regarded as a critical signaling pathway for the cardioprotective effect of osthole in rats with AMI. By contrast, it has been demonstrated that the activation of JNK and p38 MAPK exerts deleterious effects on post-ischemic myocardial apoptosis and cardiac function recovery (35). It was previously found that the inhibition of JNK1 markedly suppressed reoxygenation-induced apoptosis in rat cardiac myocytes (36). However, the activation of JNK by transfection with MKK7 in cardiomyocytes, an upstream activator of JNK, has been shown to induce myocardial hypertrophy, but not apoptosis (9). In terms of p38 MAPK, the inhibition of the cardiac p38 MAPK pathway by SB203580, a specific inhibitor, was shown to delay ischemic cell death in the pig myocardium (37). In line with these findings, our data demonstrated a marked elevation in p-JNK (the activated form of JNK) and p-p38 (the activated form of p38) in rats with AMI. Furthermore, treatment with osthole significantly diminished the expression of p-JNK and p-p38 in the rats with AMI. Taken together, the activation of ERK and the suppression of JNK, as well as p38 signaling pathways are conceived of as one of the most important cardioprotective mechanisms of osthole against myocardial infarction-induced cardiomyocyte apoptosis in rats.

Myocardial infarction often occurs when the myocardial blood supply is interrupted suddenly or persistently, and this contributes to marked cardiomyocyte apoptosis. Caspases are evolutionarily conserved cysteiny1 proteases which play a pivotal role in the initiation and execution of cellular apoptosis (38); caspase-3 serves as an executioner molecule and is the most abundant caspase under normal and pathological conditions. A previous study illustrated that caspase-3 activation of caspase-3 DNase, and this eventually led to DNA fragmentation and cell loss (39). In addition, a marked elevation in caspase-3 has been observed in Wistar rats with isoproterenol-induced AMI (40). The results from our current study revealed that the levels of caspase-3 in the infarcted rat hearts were altered and that treatment with osthole downregulated caspase-3 in the rats with AMI. It is plausible that the beneficial effects of osthole are associated with its regulation of caspase-3, finally exerting anti-apoptotic effects on infarcted rat hearts. Of note, treatment with osthole reduced caspase-3 and caspase-9 activities, which implies that osthole protects myocardial cells and decreases cellular apoptosis. In a previous study, it was demonstrated that osthole significantly reduced the activity of caspase-3 in PC12 cells (41). Ding et al emphasized that osthole inhibited the proliferation of human osteosarcoma cells through the expression of Bcl-2, Bax and caspase-3 (42). Zheng et al also illustrated that osthole ameliorated renal ischemia-reperfusion injury in rats by decreasing caspase-3 activity (43).
In conclusion, this study demonstrated the cardioprotective effects of osthole, and that its cardioprotective effects may be associated with the inhibition of inflammatory reactions, the decrease in MMP-2 expression and the activation of p-ERK. These findings suggest that osthole has the potential to be used as a drug for the treatment of AMI.

References


